Alembic Pharmaceuticals has informed about a press release dated December 09, 2015 titled ‘Rhizen Pharmaceuticals announces Exclusive Worldwide License Agreement for the Development and Commercialization of a Dual PI3K-delta gamma Inhibitor’.
The above information is a part of company’s filings submitted to BSE.